Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors

@inproceedings{Awada2012PhaseIS,
  title={Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors},
  author={Ahmad Hussein Awada and Herlinde Dumez and Alain Hendlisz and Pascal Wolter and Tatiana Besse-Hammer and Martina Uttenreuther-Fischer and Peter Stopfer and F. Fleischer and Martine J. Piccart and Patrick Sch{\"o}ffski},
  booktitle={Investigational New Drugs},
  year={2012}
}
Background A phase I study to assess the maximum tolerated dose (MTD) of a short course of afatinib in combination with docetaxel for the treatment of solid tumors. Methods Patients with advanced solid malignancies received docetaxel 75 mg/m2 intravenously on day 1 and oral afatinib once daily on days 2–4, in 3-week treatment cycles. The afatinib dose was escalated in successive cohorts of 3–6 patients until dose-limiting toxicity (DLT). The MTD cohort was expanded to 13 patients… CONTINUE READING
11 Citations
28 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Pharmacodynamic separation of erlotinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC): Overcoming hypothesized antagonism

  • A Davies, P Hesketh, +6 authors D Gandara
  • ASCO Meeting Abstracts
  • 2007
Highly Influential
3 Excerpts

Phase I trial of the irrevisible ErbB1 (EGFR) and ErbB2 (HER2) kinase inhibitor BIBW 2992 in patients with advanced solid tumours

  • TA Yap, L Vidal, +13 authors R Plummer
  • J Clin Oncol
  • 2010
2 Excerpts

A Phase I dose escalation trial of BIBW 2992, an irreversible EGFR/HER2 kinase inhibitor, for 20 and 13 days in combination with docetaxel every 21 days

  • J Marshall, GI Shapiro, P Terlizzi, P Stopfer, A Amelsberg, M Gordon
  • 2008
2 Excerpts

Similar Papers

Loading similar papers…